China's National Medical Products Administration accepted the application of Beijing Aosaikang Pharmaceutical's (SHE:002755) unit, Jiangsu Aosaikang Pharmaceutical, for the marketing authorization of maltol iron capsules, according to a Shenzhen bourse filing on Tuesday.
Shield TX (UK) developed the drug for the treatment of iron deficiency in adults.
The pharmaceutical company's shares slipped less than 2% during the afternoon trade.